Phase 2 N=14 Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
Cystic Fibrosis
Primary: 6 Minute Walk Distance — 25.2; 0.75 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=62 Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging
Pulmonary Vascular Disease
Primary: Participants Determined to be True Positives for Pulmonary Arterial Hypertension — 10; 15; 10; 5 Participants
N/A N=30 PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
Phase 2 N=15 Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Phase 2 N=36 Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease
Pulmonary Hypertension · Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in 6 Minute Walk Test — 7.00; 16.60; 16.00; 4.90 Meters walked in 6 minutes
Phase 4 N=5 Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9
N/A N=103 Assessmet of Patients With PAH Right Ventricular Volume
Pulmonary Arterial Hypertension
Primary: Observed Mean (Std Err) for % Difference Between VMS and MRI. — 4.80; 1.76; 2.03 Percent difference
Phase 3 N=30 Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
Congestive Heart Failure · Heart Failure, Left-Sided · Left-Sided Heart Failure
Primary: Change in 20 Watt Exercise Pulmonary Vascular Resistance (PVR) — -0.6; 0.1 wood units — p=0.003
Phase 4 N=19 Hypoxic Pulmonary Vasoconstriction Pilot Study
Emphysema
Primary: Perfused Blood Volume Assessed for a Change in Lung Inflammation Pre and Post Dose Sildenafil Administration — 0.37; 0.42 coefficient of variation — p=<0.05
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Phase 2 N=15 Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension · Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — 230 meters
Phase 2 N=10 Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH
Pulmonary Arterial Hypertension
Primary: Difference in Ambulatory 6 Minute Walk Distance (6MWD) Pulmonary Artery (PA) Pressures (Systolic, Diastolic, Mean) Between the Post-intervention (iNO+) and…
Phase 3 N=180 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement) — 9; 6 participants — p=0.39
N/A N=139 Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events
Pulmonary Thromboembolisms · Pulmonary Embolism
Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
N/A N=8 Bosentan and Pulmonary Endothelial Function
Pulmonary Arterial Hypertension
Primary: Acetylcholine Vascular Reactivity Response — 180 percentage of baseline
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
Phase 3 N=70 Iloprost Power 15 in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883
Phase 2 N=29 Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Alveolitis, Fibrosing · Fibrosis, Pulmonary · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Test — -26; -7 meters
Phase 3 N=30 Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Portopulmonary Hypertension
Primary: Change in Pulmonary Vascular Resistance — 7.1 percent difference from baseline
N/A N=172 The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions
Peripheral Artery Disease
Primary: Major Adverse Events (MAEs) Within 30 Days — 2 Participants
N/A N=60 Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Flow-Mediated Dilation (FMD) — 3.1; 6.7; 4.7; 6.9 percentage of change in FMD — p=<0.05
N/A N=746 Pulmonary Embolism as a Cause of COPD Exacerbations
Pulmonary Embolism · Chronic Obstructive Pulmonary Disease
Primary: All-cause Mortality, Symptomatic Venous Thromboembolism Recurrence, or Need for Readmission. — 110; 107 Participants
N/A N=16 Pressure Variability Study
Heart Failure
Primary: Mean Change in Pulmonary Artery Pressure (PAP) Due to Change in Posture — 27.7 mmHg — p=0.429
Phase 2 N=21 11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension
Pulmonary Hypertension
Primary: Changes in RV Function — 7.56 percentage
Phase 2 N=151 Selonsertib in Adults With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214
Phase 2 N=57 Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Pulmonary Hypertension
Primary: Pulmonary Vascular Resistance (PVR) Ratio of Week 12 to Baseline — 0.585; 0.757 Ratio — p=0.0158
Phase 3 N=357 Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
Hypertension, Pulmonary
Primary: Number of Participants With Adverse Events (AEs) — 184; 334 participants
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants